Hegde Yashoda Mariappa, Theivendren Panneerselvam, Srinivas Geetha, Palanivel Monashilpa, Shanmugam Nivetha, Kunjiappan Selvaraj, Vellaichamy Sivakumar, Gopal Murugananthan, Dharmalingam Senthil Rajan
Department of Pharmaceutics, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu 637205, India.
Department of Pharmaceutical Chemistry, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamilnadu 637205, India.
Anticancer Agents Med Chem. 2023;23(1):37-59. doi: 10.2174/1871520622666220513160706.
Cervical cancer is one of the leading causes of female death, with a mortality rate of over 200,000 per year in developing countries. Despite a decrease in cervical cancer occurrences in developed countries over the last decade, the frequency of the disease in developing nations continues to rise at an alarming rate, particularly when it is linked to the human papillomavirus (HPV). With just a few highly invasive conventional therapies available, there is a clear need for novel treatment options such as nanotechnology-based chemotherapeutic drug delivery.
Traditional anticancer therapy is limited by poor drug potency, non-specificity, unwanted side effects, and the development of multiple drug resistance (MDR), leading to a decrease in long-term anticancer therapeutic efficacy. An ideal cancer therapy requires a personalized and specialized medication delivery method capable of eradicating even the last cancer cell responsible for disease recurrence.
Nanotechnology provides effective drug delivery mechanisms, allowing it to serve both therapeutic and diagnostic purposes. Nanotechnology-based formulations are widely used to accurately target the target organ, maintain drug load bioactivity, preferentially accumulate the drug at the target location, and reduce cytotoxicity.
The key benefits of this drug delivery are that it improves pharmacological activity, solubility, and bioavailability and reduces toxicity in the target tissue by targeting ligands, allowing for new innovative treatment methods in an area that is desperately required. The goal of this review is to highlight possible research on nanotechnologybased delivery systems for cancer detection and treatment.
宫颈癌是女性死亡的主要原因之一，在发展中国家每年有超过20万的死亡率。尽管在过去十年中发达国家宫颈癌的发病率有所下降，但发展中国家该疾病的发病率仍以惊人的速度持续上升，尤其是与人类乳头瘤病毒（HPV）相关时。由于仅有少数几种高度侵入性的传统疗法，显然需要诸如基于纳米技术的化疗药物递送等新型治疗选择。
传统抗癌疗法受到药物效力差、非特异性、不良副作用以及多重耐药性（MDR）发展的限制，导致长期抗癌治疗效果下降。理想的癌症治疗需要一种个性化和专门的药物递送方法，能够根除即使是导致疾病复发的最后一个癌细胞。
纳米技术提供了有效的药物递送机制，使其能够同时用于治疗和诊断目的。基于纳米技术的制剂被广泛用于精确靶向目标器官、维持药物负载的生物活性、优先在目标位置积累药物并降低细胞毒性。
这种药物递送的关键优势在于它通过靶向配体提高了药理活性、溶解度和生物利用度，并降低了目标组织中的毒性，从而在迫切需要的领域实现了新的创新治疗方法。本综述的目的是强调基于纳米技术的癌症检测和治疗递送系统的可能研究。
